Thermo Fisher Opens GMP-certified Ultra-cold Facility in Netherlands

Thermo Fisher Scientific has inaugurated a GMP-certified ultra-cold facility in Bleiswijk, Netherlands, to enhance its clinical trial network in Europe. This state-of-the-art facility supports the development of advanced therapies, including cell and gene therapies, biologics, and vaccines through comprehensive services, including ambient to cryogenic storage, clinical packaging, labeling, and distribution. The site, which is gas-free and uses 15% solar power, aligns with Thermo’s sustainability goals and the company says it will support its broader effort to advance global clinical research.

Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines.

To meet increasing demand from cell and gene therapy clinical trials in Europe, this state-of-the-art facility builds on the company’s market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. The facility enables customers to meet clinical trial requirements regardless of scale or phase by leveraging its highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies.

“The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies,” said Molly Flick, vice president and general manager, bioservices & specialty logistics, Thermo Fisher Scientific.

The site, 30 minutes outside of Amsterdam, offers clinical and commercial packaging services for cell and gene therapy products from development to commercialization, as well as end to end biorepository storage solutions and associated supply chain services. Capabilities include 5,000-square-meters (54,000 square feet) of ambient to cryogenic storage, ancillaries, and cold chain packaging, labeling, distribution as well as clinical QP release services.

In support of Thermo Fisher’s commitment to sustainability and its global goal of achieving net-zero emissions by 2050, the Bleiswijk site uses 15% solar power and operates completely gas-free, provides sustainable heating and cooling with eco-friendly electric heat pumps, and uses ultramodern heat recovery technology.

For more, please find the original story source here.

Previous
Previous

Lotte Biologics and Merck KGaA Partner to Boost Biopharma Production

Next
Next

Kindeva Expands UK Facilities for Green Propellant Growth